Antinuclear Antibody Test Market to reach $4,262.32 million by 2035

Antinuclear antibody test market was valued at $2,117.10 million in 2025 and is projected to reach $4,262.32 million by 2035, growing at a CAGR of 7.3% during the forecast period 2026 to 2035, according to a new report by Orion Market Research. The Antinuclear Antibody (ANA) test market is primarily driven by the rising prevalence of autoimmune diseases, increasing demand for early and accurate diagnosis, growing awareness among clinicians and patients, and expanding laboratory infrastructure globally. Among these, technological advancements have emerged as the major growth driver. The integration of AI and digital microscopy in ANA testing is improving accuracy, reducing human error, shortening turnaround times, and enabling high-throughput screening.

Browse the full report description of “Antinuclear Antibody (ANA) Test Market Size, Share & Trends Analysis Report by Product Type (Assay Kits & Reagents, Antinuclear Antibody Test System, and Antinuclear Antibody Test Software), by Test Type (Indirect Immunofluorescence, Enzyme-Linked Immunosorbent Assay (ELISA), and Multiplex Testing), by Disease Type (Systemic Lupus Erythematosus, Sjogren’s Syndrome, Rheumatoid Arthritis, Scleroderma, and Others), and by End-User (Hospitals and Clinical Laboratories), Forecast Period (2026-2035)” of https://www.omrglobal.com/industry-reports/antinuclear-antibody-ana-test-market

Digital Microscopy and AI are accelerating ANA Test Adoption

The adoption of AI and digital microscopy is transforming the Antinuclear Antibody (ANA) test market by addressing historical limitations and enhancing clinical utility. AI eliminates inter-observer variability, providing consistent pattern recognition that increases clinician confidence and encourages higher test utilization. It also enables high-accuracy negative screening, automatically filtering out negative samples, optimizing pathologist resources, and lowering cost-per-test, which expands market reach.

Digital platforms significantly reduce turnaround times and enable high-throughput screening, making ANA tests viable in acute clinical settings and driving larger order volumes from hospitals. Advanced AI can precisely quantify antibody titers and detect complex patterns, allowing clinicians to monitor disease progression or therapeutic response more effectively.

Moreover, AI systems can integrate with laboratory information systems (LIS) to automatically record and store results, reducing manual errors and enabling faster decision-making, particularly beneficial for large-scale labs. Remote review of digital slides allows smaller hospitals and clinics to send samples to centralized labs without compromising quality.

Together, these innovations expand access, streamline workflows, and increase testing volumes, fueling sustained growth in the global ANA test market.

Recent Key Developments in the Antinuclear Antibody Test Market

• In September 2025, Labcorp announced a collaboration with Roche to implement the company's FDA-cleared VENTANA DP 600 and DP 200 slide scanners. The investment enables pathologists to diagnose patients using digital images and supports future artificial intelligence (AI) integration.

• In July 2024, AliveDx unveiled its LumiQ automated immunofluorescence assay (IFA) solution, a comprehensive, automated platform for autoimmune diagnostics that includes high-throughput ANA testing capabilities. The system automates IFA slide processing, imaging, and classification, improving efficiency, consistency, and diagnostic confidence in autoimmune labs.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
• Product Type
• Test Type
• Disease Type
• End-User

• Competitive Landscape – Abbott Laboratories, Bio Rad Laboratories, Inc., F. Hoffmann La Roche Ltd., Siemens Healthineers AG and Thermo Fisher Scientific Inc.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Antinuclear Antibody Test Market Report Segment

By Product Type

• Assay Kits & Reagents
• Antinuclear Antibody Test System
• Antinuclear Antibody Test Software

By Test Type

• Indirect Immunofluorescence
• Enzyme-Linked Immunosorbent Assay (ELISA)
• Multiplex Testing

By Disease Type

• Systemic Lupus Erythematosus
• Sjögren’s Syndrome
• Rheumatoid Arthritis
• Scleroderma
• Others (Addison's Disease And Pulmonary Fibrosis, Polymyositis)

By End-User

• Hospitals
• Clinical Laboratories

Global Antinuclear Antibody Test Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/antinuclear-antibody-ana-test-market